$BHC News

Bausch Health Announces Availability of Solta Medical's Fraxel FTX® in Australia

Bausch Health's Ortho Dermatologics Announces the 2026 Aspire Higher Scholarship Winners

Can Bausch (BHC) Run Higher on Rising Earnings Estimates?

Bausch (BHC) Upgraded to Buy: Here's What You Should Know

Bausch Health Announces 2026 Gastrointestinal Health Scholars Program Winners

Why Bausch Health Companies Stock Skyrocketed by Almost 40% Last Month

Bausch Health CEO Thomas J. Appio Joins Bausch + Lomb Board

Bausch + Lomb Announces Board of Directors Update, Reaffirms Guidance

Bausch Health (BHC) Rockets 28% as Q2 Turnaround Fuels Recovery Outlook

Bausch Health Companies Inc. Q2 2026 Earnings Call Summary

Bausch Health (BHC) Q2 Earnings and Revenues Beat Estimates

Bausch (BHC) Reports Q2 Earnings: What Key Metrics Have to Say

BAUSCH HEALTH ANNOUNCES SECOND QUARTER 2026 RESULTS, RAISES GUIDANCE

(Pr)ELIDEL® (pimecrolimus) cream Now Reimbursed Under Alberta's Public Drug Plan for Eligible Patients with Mild to Moderate Atopic Dermatitis

Bausch Health’s (BHC) Canadian Subsidiary Lists PrOKEDI Dosages in RAMQ Formulary

Bausch Health to Announce Second Quarter 2026 Results on July 29, 2026

Québec is the first province to list (Pr)OKEDI(MC) (extended-release injectable suspension of risperidone) on the public drug reimbursement formulary for the treatment of schizophrenia

Bausch Health Announces Quebec Provincial Listing Of Prokedi For Treatment Of Schizophrenia In Adults

Michael Goettler Resigns from Bausch Health's Board of Directors

Bausch Health: Invest In The Short-Term Bonds, Not The Stock